NCT00306670View on ClinicalTrials.gov

Trial of Rituximab Versus Oral Cyclophosphamide to Eradicate or Suppress Autoimmune Anti-Factor VIII Antibodies in Acquired Hemophilia A

PHASE2/PHASE3TerminatedINTERVENTIONAL

Enrollment

2

Participants

Timeline

Start Date

April 30, 2006

Primary Completion Date

January 31, 2011

Study Completion Date

August 31, 2011

Conditions

Hemophilia A

Interventions

DRUG

Rituxan

Acquired Hemophilia A Patients Who Have Developed Anti-Factor VIII Antibodies

DRUG

prednisone

\<30 mg/day

Sponsors

Collaborators (1)

Genentech, Inc.

All Listed Sponsors

collaborator

Genentech, Inc.

INDUSTRY

lead

Georgetown University

OTHER

NCT00306670 - Trial of Rituximab Versus Oral Cyclophosphamide to Eradicate or Suppress Autoimmune Anti-Factor VIII Antibodies in Acquired Hemophilia A | Biotech Hunter | Biotech Hunter